Why IgG4-Related Disease Requires a Team, Not a Single Specialist

No single specialist sees the full spectrum of IgG4-related disease, according to Allison Yang, M.D., M.P.H., medical director of the Pancreas Program at Weill Cornell Medicine. Rheumatologists often identify it through gland swelling or retroperitoneal fibrosis, gastroenterologists like Yang see pancreas or biliary tree involvement, radiologists recognize characteristic imaging patterns, and pathologists confirm findings through biopsy. Yang said patients are diagnosed fastest when these specialists are actively communicating rather than working in isolation.

At Weill Cornell, that communication takes the form of weekly multidisciplinary conferences where cases are reviewed across specialties. Yang said the goal is to ensure that every specialist involved — radiologists, gastroenterologists performing biopsies, and pathologists interpreting them — knows to keep IgG4-related disease on their diagnostic radar, including staining specifically for IgG4 when appropriate. Coordinating five or six subspecialists weekly is logistically difficult, she said, but it remains a priority because cross-specialty communication directly expedites diagnosis and care.

Moving Beyond Steroids

Yang described steroids as addressing the visible inflammation, “suppressing the fire,” without addressing the underlying immune activity driving it. B-cell-depleting therapies target that underlying driver more directly. Rituximab was the first viable steroid-sparing option, and newer agents like inebilizumab deplete B-cells even more completely, with additional therapies in development.

Yang said she now views IgG4-related disease less as a onetime acute illness and more as a chronic, relapsing condition, drawing a comparison to how inflammatory bowel disease is managed: addressing the underlying driver of inflammation proactively rather than only treating flares as they occur. She said the field is moving toward biomarker-guided care, where monitoring trends over time could allow clinicians to treat, or even prevent, relapses before a full flare develops.

The Core Takeaway

Yang emphasized that IgG4-related disease is a highly effective mimicker of other conditions, which makes it easy to miss if it isn’t actively considered during evaluation. Keeping it on the differential, she said, helps prevent patients from being funneled too far down a single diagnostic pathway, and catching the disease early can prevent significant downstream damage.